Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
NCT05862324 · View on ClinicalTrials.gov ↗
Study Summary
TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase ½ study that aims to establish safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-CLDN18.2.
Conditions Studied
Interventions
- BIOLOGICAL TAC01-CLDN18.2
Study Locations (9)
California
- University of Southern California — Los Angeles
- University of California San Diego — San Diego
Florida
- University of Miami Sylvester Comprehensive Cancer Center — Miami
Massachusetts
- Dana Farber Cancer Institute — Boston
New York
- Memorial Sloan Kettering Cancer Center — New York
Ohio
- Cincinnati Cancer Center — Cincinnati
Texas
- MD Anderson Cancer Center — Houston
Ontario
- Princess Margaret Cancer Center — Toronto
Quebec
- Centre hospitalier de l'Université de Montréal — Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2023-08-23 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05862324
The ClinicalTrials.gov registry entry for NCT05862324 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Triumvira Immunologics, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Metastatic Solid Tumor appearing as the primary indexed condition, and to 1 intervention — of which TAC01-CLDN18.2 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05862324 reports 9 study locations spanning 8 distinct geographic areas — top geographies include California, Florida, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05862324 about?
NCT05862324 is a clinical study titled "TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)". TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell ...
What is the current status of trial NCT05862324?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2023-08-23. Estimated completion is 2027-08-01.
What conditions does trial NCT05862324 study?
This clinical trial studies the following conditions: Metastatic Solid Tumor. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05862324?
The interventions under investigation include: TAC01-CLDN18.2 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05862324?
This trial is sponsored by Triumvira Immunologics, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05862324 being conducted?
This trial has 9 study locations across California, Florida, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.